堅瑞沃能(300116.SZ): 重整計劃中資本公積轉增股本的股權登記日為3月31日
格隆匯3月25日丨堅瑞沃能(300116.SZ)公佈,根據陝西省西安市中級人民法院裁定批准的《陝西堅瑞沃能股份有限公司重整計劃》(“重整計劃”),此次資本公積轉增股本以公司現有總股本為基數,按每10股轉增8.5股的比例實施資本公積轉增股本,共計轉增約20.68億股股份。轉增後,公司總股本由約24.33億股增加至約45.00億股。此次資本公積轉增股份將直接登記至管理人證券賬户(陝西堅瑞沃能股份有限公司破產企業財產處置專用賬户),由管理人按照重整計劃的規定進行分配和處置。此次股權登記日:2020年3月31日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.